Multiple opioid receptors mediate the hypotensive response induced by central 5-HT3 receptor stimulation

Neuropeptides

Volumn 45, Issue 3, 2011, Pages 219-227

  Fregoneze, J B ^a   Oliveira, E F ^a   Ribeiro, V F ^b   Ferreira, H S ^b   De Castro e Silva, E ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSIDADE DO ESTADO DA BAHIA   (Brazil)

Author keywords

5 HT3 receptors; Blood pressure; Opioid receptors

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; ONDANSETRON; OPIATE ANTAGONIST; OPIATE RECEPTOR; SEROTONIN 3 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; HYPERTENSION; HYPOTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SEROTONINERGIC SYSTEM;

ANIMALS; BIGUANIDES; BLOOD PRESSURE; HEART RATE; HYPOTENSION; MALE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; ONDANSETRON; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

ANIMALIA; RATTUS;

EID: 79955615986     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2011.03.004     Document Type: Article

References (77)

1. Bodnar R.J. Endogenous opiates and behavior: 2008. Peptides 2009, 30:2432-2479.
2. Bruchas M.R., Land B.B., Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010, 1314:44-55.
3. Caeiro X., Vivas L. Beta-Endorphin in the median preoptic nucleus modulates the pressor response induced by subcutaneous hypertonic sodium chloride. Exp. Neurol. 2008, 210:59-66.
4. Cavun S., Resch G.E., Evec A.D., Rapacon-Baker M.M., Millington W.R. Blockade of delta opioid receptors in the ventrolateral periaqueductal gray region inhibits the fall in arterial pressure evoked by hemorrhage. Pharmacol. Exp. Ther. 2001, 297:612-619.
5. Champion H.C., Zadina J.E., Kastin A.J., Kadowitz P.J. Endomorphin 1 and 2 have vasodepressor activity in the anesthetized mouse. Peptides 1998, 18:1393-1397.
6. Chaouloff F., Berton O., Mormède P. Serotonin and stress. Neuropsychopharmacology 1999, 21:28S-32S.
7. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci. 1991, 48:1991-2003.
8. Chu L.F., Liang D.Y., Li X., Sahbaie P., D'arcy N., Liao G., Peltz G., David Clark J. From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics. Pharmacogenet. Genomics 2009, 19:193-205.
9. Corne S.J., Pickering R.W., Warner B.T. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br. J. Pharmacol. Chemother. 1963, 20:106-120.
10. Costall B., Naylor R.J. Anxiolytic potential of 5-HT3 receptor antagonists. Pharmacol. Toxicol. 1992, 70:157-162.
11. 3 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3:27-37.
12. Côté F., Fligny C., Fromes Y., Mallet J., Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 2004, 10:232-237.
13. D'Addario C., Di Benedetto M., Izenwasser S., Candeletti S., Romualdi P. Role of serotonin in the regulation of the dynorphinergic system by a kappa-opioid agonist and cocaine treatment in rat CNS. Neuroscience 2007, 144:157-164.
14. D'Amato R., Holaday J.W. Multiple opioid receptors in endotoxic shock: evidence for delta involvement and mu-delta interactions in vivo. Proc. Natl. Acad. Sci. USA 1984, 81:2898-2901.
15. De Wardener H.E. The hypothalamus and hypertension. Physiol. Rev. 2001, 81:1599-1658.
16. Drolet G., Dumont E.C., Gosselin I., Kinkead R., Laforest S., Trottier J.F. Role of endogenous opioid system in the regulation of the stress response. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:729-741.
17. Faden A.I., Feuerstein G. Hypothalamic regulation of the cardiovascular and respiratory systems: role of specific opiate receptors. Br. J. Pharmacol. 1983, 109:997-1002.
18. Feldman P.D., Parveen N., Sezen S. Cardiovascular effects of Leu-enkephalin in the nucleus tractus solitarius of the rat. Brain Res. 1996, 709:331-336.
19. 3 receptors in the control of blood pressure in stressed and non-stressed rats. Brain Res. 2004, 1028:48-58.
20. 2C agonist mCPP on blood pressure and heart rate in rats. Brain Res. 2005, 1040:64-72.
21. Feuerstein G., Sirén A.L. The opioid system in cardiac and vascular regulation of normal and hypertensive states. Circulation 1987, 75:I125-I129.
22. Feuerstein G., Sirén A.L. Hypothalamic mu-opioid receptors in cardiovascular control: a review. Peptides 1988, 9(Suppl. 1):75-78.
23. Fichna J., Janecka A., Costentin J., Do Rego J.C. The endomorphin system and its evolving neurophysiological role. Pharmacol. Rev. 2007, 59:88-123.
24. Fields H.L., Basbaum A.I. Central nervous system mechanisms of pain modulation. Textbook of Pain 1994, 243-257. Churchill Livingstone, New York. 3rd ed. P.D. Wall, P. Melzack (Eds.).
25. Frithiof R., Eriksson S., Rundgren M. Central inhibition of opioid receptor subtypes and its effect on haemorrhagic hypotension in conscious sheep. Acta Physiol. 2007, 191:25-34.
26. 4 receptor antagonists. Med. Res. Rev. 1997, 17:163-214.
27. George S.R., Zastawny R.L., Briones-Urbina R., Cheng R., Nguyen T., Heiber M., Kouvelas A., Chan A.S., O'Dowd B.F. Distinct distributions of mu, delta and kappa opioid receptor mRNA in rat brain. Biochem. Biophys. Res. Commun. 1994, 205:1438-1444.
28. Goldstein D.J., Kulakowski E.C., Ropchak T.G., Brown P., Keiser H.R. Naloxone reverses the serotonin dependent hypotensive action of CGP 6085 A. Life Sci. 1987, 41:1369-1373.
29. Gregory R.E., Ettinger D.S. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998, 55:173-189.
30. Guyenet P.G., Stornetta R.L., Schreihofer A.M., Pelaez N.M., Hayar A., Aicher S., Llewellyn-Smith I.J. Opioid signalling in the rat rostral ventrolateral medulla. Clin. Exp. Pharmacol. Physiol. 2002, 29:238-242.
31. Gyermek L. 5-HT3 receptors: pharmacologic and therapeutic aspects. J. Clin. Pharmacol. 1995, 35:845-855.
32. Hagan R.M.G., Kilpatrick J., Tyers M.B. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology 1993, 112:S68-S75.
33. Henderson L.A., Keay K.A., Bandler R. Delta- and kappa-opioid receptors in the caudal midline medulla mediate haemorrhage-evoked hypotension. NeuroReport 2002, 13:729-733.
34. Holaday J.W. Cardiovascular effects of endogenous opiate systems. Annu. Rev. Pharmacol. Toxicol. 1983, 23:541-594.
35. Johnson M.W., Mitch W.E., Wilcox C.S. The cardiovascular actions of morphine and the endogenous opioid peptides. Prog. Cardiovasc. Dis. 1985, 27:435-450.
36. Keay K.A., Crowfoot L.J., Floyd N.S., Henderson L.A., Christie M.J., Bandler R. Cardiovascular effects of microinjections of opioid agonists into the 'Depressor Region' of the ventrolateral periaqueductal gray region. Brain Res. 1997, 762:61-71.
37. Kitchen I., Slowe S.J., Matthes H.W.D., Kieffer B.L. Quantitative autoradiographic mapping of μ-, δ- and κ-opioid receptors in knockout mice lacking the μ-opioid receptor gene. Brain Res 1997, 778:73-88.
38. Ku Y.H. Role of limbic peptidergic circuits in regulation of arterial pressure, relevant to development of essential hypertension. Neuropeptides 2006, 40:299-308.
39. Kwiat G.C., Basbaum A.I. The origin of brainstem noradrenergic and serotonergic projections to the spinal cord dorsal horn in the rat. Somatosens. Mot. Res. 1992, 9:157-173.
40. Lanfumey L., Mongeau R., Cohen-Salmon C., Hamon M. Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci. Biobehav. Rev. 2008, 32:1174-1184.
41. Lang R.E., Brückner U.B., Kempf B., Rascher W., Sturm V., Unger T., Speck G., Ganten D. Opioid peptides and blood pressure regulation. Clin. Exp. Hypertens. A 1982, 4:249-269.
42. Laubie M., Schmitt H., Vincent M., Remond G. Central cardiovascular effects of morphinomimetic peptides in dogs. Eur. J. Pharmacol. 1977, 46:67-71.
43. Mansour A., Fox C.A., Akil H., Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995, 18:22-29.
44. McConnaughey M.M., Zhai Q.Z., Ingenito A.J. Effects of rat brain kappa 1- and kappa 2-opioid receptors after chronic treatment with non-peptide kappa-agonists. J. Pharm. Pharmacol. 1998, 50:1121-1125.
45. Mezey E., Young W.S., Siegel R.E., Kovács K. Neuropeptides and neurotransmitters involved in regulation of corticotropin-releasing factor-containing neurons in the rat. Prog. Brain Res. 1987, 72:119-127.
46. Miyawaki T., Goodchild A.K., Pilowsky P.M. Activation of mu-opioid receptors in rat ventrolateral medulla selectively blocks baroreceptor reflexes while activation of delta opioid receptors blocks somato-sympathetic reflexes. Neuroscience 2002, 109:133-144.
47. Morilak D., Drolet G., Chalmers J. A lack of potency for the delta-opioid antagonist naltrindole after microinjection into the rostral ventrolateral medulla of rabbits. Clin. Exp. Pharmacol. Physiol. 1990, 17:527-530.
48. Nalivaiko E., Sgoifo A. Central 5-HT receptors in cardiovascular control during stress. Neurosci. Biobehav. Rev. 2009, 33:95-106.
49. Nozaki C., Kamei J. Possible involvement of opioidergic systems in the antinociceptive effect of the selective serotonin reuptake inhibitors in sciatic nerve-injured mice. Eur. J. Pharmacol. 2006, 552:99-104.
50. Olson G.A., Olson R.D., Vaccarino A.L., Kastin A.J. Endogenous opiates: 1997. Peptides 1998, 19:1791-1843.
51. Portoghese P.S. The design of delta-selective opioid receptor antagonists. Farmaco 1993, 48:243-251.
52. Portoghese P.S., Lipkowski A.W., Takemori A.E. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987, 40:1287-1292.
53. Portoghese P.S., Sultana M., Takemori A.E. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J. Med. Chem. 1990, 33:1714-1720.
54. Pugsley M.K. The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system. Pharmacol. Ther. 2002, 93:51-75.
55. Ramage A.G. Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Res. Bull. 2001, 56:425-439.
56. Ramage A.G., Villalón C.M. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol. Sci. 2008, 29:472-481.
57. Rao S.P., Conley A., Dunbar J.C. Cardiovascular responses to central administration of mu and kappa opioid receptor agonist and antagonist in normal rats. Peptides 2003, 24:745-754.
58. Ross C.A., Ruggiero D.A., Reis D.J. Projections from the nucleus tractus solitarii to the rostral ventrolateral medulla. J. Comp. Neurol. 1985, 245:511-534.
59. Sharif N.A., Hughes J. Discrete mapping of brain mu and delta opioid receptors using selective peptides: quantitative autoradiography species differences and comparison with kappa receptors. Peptides 1989, 10:499-522.
60. Schoffelmeer A.N., De Vries T.J., Hogenboom F., Hruby V.J., Portoghese P.S., Mulder A.H. Opioid receptor antagonists discriminate between presynaptic mu and delta receptors and the adenylate cyclase-coupled opioid receptor complex in the brain. J. Pharmacol. Exp. Ther. 1992, 263:20-24.
61. Schoffelmeer A.N., Van Vliet B.J., De Vries T.J., Heijna M.H., Mulder A.H. Regulation of brain neurotransmitter release and of adenylate cyclase activity by opioid receptors. Biochem. Soc. Trans. 1992, 20:449-453.
62. Sepúlveda M.I., Lummis S.C., Martin I.L. The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells. Br. J. Pharmacol. 1991, 104:536-540.
63. Sesack S.R., Picke V.M. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions. J. Neurosci. 1992, 12:1335-1350.
64. Sharma H.S., Nyberg F., Olsson Y. Dynorphin A content in the rat brain and spinal cord after a localized trauma to the spinal cord and its modification with p-chlorophenylalanine. An experimental study using radioimmunoassay technique. Neurosci. Res. 1992, 14:195-203.
65. Shen S., Ingenito A.J. Comparison of cardiovascular responses to intra-hippocampal mu, delta and kappa opioid agonists in spontaneously hypertensive rats and isolation-induced hypertensive rats. J. Hypertens. 1999, 17:497-505.
66. Song B., Chen W., Marvizón J.C. Inhibition of opioid release in the rat spinal cord by serotonin 5-HT(1A) receptors. Brain Res. 2007, 1158:57-62.
67. Szabó A., Butz B.L., Alper R.H. Further characterization of forebrain serotonin receptors mediating tachycardia in conscious rats. Brain Res. Bull. 1998, 45:583-588.
68. Takemori A.E., Ho B.Y., Naeseth J.S., Portoghese P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 1988, 246:255-258.
69. 3 receptors. Curr. Pharm. Des. 2006, 12:3615-3630.
70. Unal C.B., Owen M.D., Millington W.R. Cyclo(Gly-Gln) inhibits the cardiorespiratory depression produced by beta-endorphin and morphine. Brain Res. 1997, 747:52-59.
71. Urzedo-Rodrigues L.S., Ferreira H.S., Almeida D.O., Medeiros J.P., Batista A., de Castro E., Silva E., Fregoneze J.B. Blockade of 5-HT(3) receptors at septal area increase blood pressure in unanaesthetized rats. Auton. Neurosci. 2011, 159:51-61.
72. Vaccarino A.L., Kastin A.J. Endogenous opiates: 2000. Peptides 2001, 22:2257-2328.
73. Vaccarino A.L., Olson G.A., Olson R.D., Kastin A.J. Endogenous opiates: 1998. Peptides 1999, 20:1527-1574.
74. 3 receptor. J. Recept. Signal Transduct. Res. 1997, 17:267-277.
75. Vetulani J., Bednarczyk B., Reichenberg K., Rokosz A. Head twitches induced by LSD and quipazine: similarities and differences. Neuropharmacology 1980, 19:155-158.
76. Zhang Y.Q., Gao X., Ji G.C., Huang Y.L., Wu G.C., Zhao Z.Q. Expression of 5-HT1A receptor mRNA in rat lumbar spinal dorsal horn neurons after peripheral inflammation. Pain 2002, 98:287-295.
77. Zimmerman D.M., Leander J.D. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J. Med. Chem. 1990, 33:895-902.